Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • Refractive
  • Cataract
  • Glaucoma
  • Cornea
  • Retina
  • Practice Mgmt.
  • OTE
  • Job Board
MJH Life Sciences

SUBSCRIBE: Print / Digital / eNewsletter

Cenegermin receives European Commission marketing authorization

  • Laird Harrison
August 30, 2017
  • Cornea OTE, Cornea OTE, Modern Medicine Cases, Modern Medicine Feature Articles, Modern Medicine News, Ophthalmology, OTE Articles, Retina OTE, Cornea, OTE Articles, Retina

The European Commission has granted marketing authorisation for cenegermin eye drops (Oxervate, Dompé) for the treatment of moderate to severe neurotrophic keratitis.

It is the first drug authorised by the European Commission for adults in Europe with neurotrophic keratitis, a severely debilitating eye disease which affects fewer than 5 out of 10,000 people.

Related: EMA committee recommends cenegermin for neurotrophic keratitis

“Considering the severity of the disease and the lack of viable alternatives, having a therapeutic option that can act on corneal lesions is an important development for the community of ophthalmologists and to the patients themselves,” said Harminder Singh Dua, chair and professor of ophthalmology, University of Nottingham.

Cenegermin received orphan drug designation for neurotrophic keratitis in 2015.

In this condition, damage to the trigeminal nerve or its branches causes loss of sensation in the cornea. In the most severe cases, it can lead to ulcers, aseptic necrosis and corneal perforation, resulting in impaired vision of those affected.

The initial damage can result from herpes simplex and herpes zoster viral infections, trigeminal neuralgia surgery, acoustic neuroma, and toxicity from chronic use of topical ocular medications.

The sensory neurons in the cornea directly influence the integrity of the corneal epithelium; without them epithelial cells swell, lose microvilli, and produce abnormal basal lamina. This can slow mitosis, leading to epithelial breakdown.

This makes the cornea prone to injury that can lead to corneal ulcers, perforation, infection, and scarring.

Discontinuation of medications that caused the syndrome may allow healing, but until now, no medication could restore decreased corneal sensitivity or induce corneal healing.

Cenegermin is the recombinant version of the human nerve growth factor (NGF) discovered by Nobel Laureate Rita Levi Montalcini. This protein is naturally produced by the human body and is involved in the development, maintenance, and survival of nerve cells.

Dompé produces cenegermin through recombinant DNA technology, with the introduction of a gene (DNA) into bacteria, causing them to produce the human nerve growth factor.

Nerve regeneration

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Dry Eye Awareness
  • Ocular Surface Disease
  • Wet AMD
  • IOL Advances
  • Therapeutic Cataract & Refractive
Shifting The Paradigm for Retinal Disease Management: The Value of Modern Electroretinography
Video on CATALYS® Laser System presented by Johnson & Johnson
Video on WHITESTAR SIGNATURE® PRO System by Johnson & Johnson
CME Activities
DEXYCU® (dexamethasone intraocular suspension) 9% Case Study Series

Current Issue

Ophthalmology Times: Nov. 15, 2019
Nov 20, 2019 Vol 44 No 19
Digital Edition
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".